Cardiotoxicity of 5-fluorouracile;Cardiotoxicité du 5-fluoro-uracile

Bulletin du Cancer

Volumn 91, Issue SPEC. ISS., 2004, Pages

  Teixeira, Luis ^a   Barry, Sonia ^b   Debourdeau, Philippe ^c   Cohen, Ariel ^a   Tournigand, Christophe ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c Service de medecine interne   (France)

Author keywords

5 fluorouracil; Cardiotoxicity

Indexed keywords

FLUOROURACIL;

CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DIARRHEA; DRUG EFFICACY; ELECTROCARDIOGRAM; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; PATHOPHYSIOLOGY; PROGNOSIS; PROPHYLAXIS; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; CORONARY THROMBOSIS; CORONARY VESSELS; DEOXYCYTIDINE; ELECTROCARDIOGRAPHY; FLUOROURACIL; HEART; HEART DISEASES; HUMANS; MYOCARDITIS;

EID: 10044249020     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Heidelberger C, et al. Fluotinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-6.
2. Gaveau T, et al. Cardiovascular disorders in the course of antimitotic infusions at high doses. 30 clinical cases. Anesth Analg 1969; 26: 311-27 (Paris).
3. Dent RG, McColl I. Letter: 5-fluorouracil and angina. Lancet 1975; 1: 347-8.
4. Labianca R, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505-10.
5. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Rev Cancer 2003; 3: 330-8.
6. Freeman NJ, Costanza ME. 5-fluorouracil-associated cardiotoxicity. Cancer 1988; 61: 36-45.
7. Lieutaud T, et al. 5-fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer 1996; 32A: 368-9.
8. Cwikiel M, et al. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 1996; 7: 731-7.
9. Thyss A, et al. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol 1992; 3: 88.
10. Porta C, et al. Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 1998; 45: 81-2.
11. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: acritical review. Ann Oncol 1990; 1: 409-14.
12. Kuzel T, et al. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990; 65: 885-9.
13. Cwikiel M, et al. Changes of blood viscosity in patients treated with 5-fluorouracil: a link to cardiotoxicity? Acta Oncol 1995; 34: 83-5.
14. Levillain R. Experimental myocarditis; anatomical study of 210 tat hearts after ingestion of 5-fluorouracil. C R Seances Soc Biol Fil 1972; 166: 340-2.
15. Sasson Z, et al. 5-fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 1994; 10: 861-4.
16. Grandi AM, et al. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and Low doses of folinic acid: a one-year follow-up study. Ann Oncol 1997; 8: 705-8.
17. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive catdiopathy. Cancer 1993; 71: 493-509.
18. Lemaire L, et al. Catdiotoxicity of 5-fluorouracil: a question of formulation. Bull Cancer 1994; 81: 1057-79.
19. Etienne MC, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-53.
20. de Gramont A, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-15.
21. Becker K, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57: 475-84.
22. Aziz SA, et al. Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. Clin Oncol (R Coll Radiol) 1998; 10: 377-8.
23. Rezkalla S, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7: 509-14.
24. Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am J Med 1988; 85: 750-1.
25. Cianci G, et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003; 88: 1507-9.
26. Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 1990; 29: 1001-3.
27. Bertolini A, et al. Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001; 87: 200-6.
28. Desrame J, et al. Coronary insufficiency after an oral intake of capecitabine. Gastroenterol Clin Biol 2001; 25: 829-30.
29. Frickhofen N, et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13: 797-801.
30. Schnetzler B, et al. Coronary spasm induced by capecitabine. Ann Oncol 2001; 12: 723-4.
31. Van Cutsem E, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that repotted with 5-fluorouracil. Ann Oncol 2002; 13: 484-5.
32. Camps C, Godes M, Soler JJ. Possible cardiotoxicity induced by orally administered fluoropyrimidines. An Med Interna 1990; 7: 525-7.